

factor IX deficiency, (2) is free from contamination by poxviruses and by <sup>all</sup> plasma constituents, and (3) has a specific activity defined as the ratio:

Concentration of test sample required to clot a given volume of factor IX-deficient plasma in a given time by the kaolin-cephalin method

Concentration of factor IX protein in the test sample as determined by ELISA

of at least 90% of that of average normal human plasma.

18. Factor IX protein according to claim 17 having a specific activity of 100%.

19. A method of treating a human patient suffering from a deficiency of factor IX, said method comprising administering to the patient a biologically active recombinant DNA-derived factor IX protein ~~derived from a single human individual~~ which (1) has an amino acid sequence of human factor IX protein or of a protein sufficiently similar thereto to make it acceptable for infusion into human patients suffering from factor IX deficiency, (2) is free from contamination by poxviruses and by <sup>all</sup> plasma constituents, and (3) has a specific activity defined as the ratio:

Concentration of test sample required to clot a given volume of factor IX-deficient plasma in a given time by the kaolin-cephalin method

Concentration of factor IX protein in the test sample as determined by ELISA

ANSON et al  
Serial No. 06/839,215

- 3 -

C<sup>1</sup>  
Cont  
of at least 90% of that of average normal human plasma.

20. A method according to claim 19 wherein the factor IX protein has a specific activity of 100%.--

---